# The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma

> **NCT04860700** · PHASE2 · COMPLETED · sponsor: **Peking Union Medical College Hospital** · enrollment: 27 (actual)

## Conditions studied

- Malignant Adrenal Gland Pheochromocytoma
- Malignant Paraganglioma
- Pheochromocytoma, Metastatic
- Paraganglioma, Malignant
- Paraganglioma, Extra-Adrenal

## Interventions

- **DRUG:** anlotinib hydrochloride

## Key facts

- **NCT ID:** NCT04860700
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-30
- **Primary completion:** 2023-10-17
- **Final completion:** 2023-10-17
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2024-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04860700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04860700, "The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04860700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*